Compare FTEK & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTEK | CRDL |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.7M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | FTEK | CRDL |
|---|---|---|
| Price | $1.57 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $9.00 |
| AVG Volume (30 Days) | 137.9K | ★ 669.0K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,713,000.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $21.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.77 |
| 52 Week High | $3.65 | $1.59 |
| Indicator | FTEK | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 46.52 |
| Support Level | $1.50 | $0.88 |
| Resistance Level | $1.88 | $1.12 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 21.05 | 52.08 |
Fuel Tech Inc is an technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.